Neurocrine Biosciences (NBIX) Gains from Investment Securities (2010 - 2026)

Neurocrine Biosciences has reported Gains from Investment Securities for 16 years, with the latest figure at $55.7 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $55.7 million; the trailing twelve-month figure through Mar 2026 stood at $55.7 million (down 87.93% YoY), and the FY2024 full-year result was $271.6 million, up 35.26% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $55.7 million, up from -$3.4 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $262.6 million in Q4 2024, with the low at -$3.4 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged $103.5 million across 4 years, with a median of $55.7 million in 2026.
• The largest YoY upside for Gains from Investment Securities was 31.96% in 2024 against a maximum downside of 31.96% in 2024.
• Neurocrine Biosciences' Gains from Investment Securities stood at $199.0 million in 2023, then surged by 31.96% to $262.6 million in 2024, then plunged by 101.29% to -$3.4 million in 2025, then surged by 1738.24% to $55.7 million in 2026.
• The last three Gains from Investment Securities figures came in at $55.7 million (Q1 2026), -$3.4 million (Q3 2025), and $3.4 million (Q2 2025), per Business Quant data.